Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Blood (2025) 146 (Supplement 1): 667.

https://doi.org/10.1182/blood-2025-667

Published: 2025

Journal Articles

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Tycel Phillips, Lu Chen, Tiffanie Barnhizer, Alex Herrera, Geoffrey Shouse, Daniel Ermann, Reem Karmali, Adam Kittai, Manali Kamdar, Diane Smith, James Godfrey, Brian Sworder, Swetha Thiruvengadam, John Baird, Avyakta Kallam, Elizabeth Budde, Alexey Danilov

Blood (2025) 146 (Supplement 1): 883.

https://doi.org/10.1182/blood-2025-883

Published: 2025

Journal Articles

Trial-in-progress: A phase 2 randomized trial of remodeling intestinal microbiota using fecal microbiome transplant (FMT) among recipients of chimeric antigen receptor T cells (CAR T)

Karamjeet Sandhu, Xinran Qi, Sally Mokhtari, Xin-Zi Emily Tang, John Baird, Alexander Khoruts, Elizabeth Budde, Robert Jenq

Blood (2025) 146 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2025-5507

Published: 2025

Journal Articles

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Elizabeth Budde, Marissa Del Real, John Baird, Lu Chen, Joo Song, Xiuli Wang, Swetha Thiruvengadam, Marie Hu, Alan Macias, Emanuela Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel (Ting-Ying) Cheng, Stephen Forman, Larry Kwak

Blood (2025) 146 (Supplement 1): 268.

https://doi.org/10.1182/blood-2025-268

Published: 2025

Journal Articles

ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C

Blood (2025) 146 (Supplement 1): 569.

https://doi.org/10.1182/blood-2025-569

Published: 2025

Journal Articles

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

Blood (2025) 146 (Supplement 1): 566.

https://doi.org/10.1182/blood-2025-566

Published: 2025

Journal Articles

Real-world evaluation of health care resource utilization, clinical effectiveness, and safety of lisocabtagene maraleucel and axicabtagene ciloleucel administered in the outpatient (OP) setting for R/R large B-cell lymphoma (LBCL)

Sagar Patel, Elise Chong, Farah Toron, Fei Fei Liu, Fangyi Gu, John Baird, Sameh Gaballa

Blood (2025) 146 (Supplement 1): 6270.

https://doi.org/10.1182/blood-2025-6270

Published: 2025

Journal Articles

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

Blood (2025) 146 (Supplement 1): 5373.

https://doi.org/10.1182/blood-2025-5373

Published: 2025

Journal Articles

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Blood (2025) 146 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2025-6364

Published: 2025

Journal Articles

Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)

Amer Beitinjaneh, Supriya Gupta, Fateeha Furqan, John Baird, Wen-Kai Weng, Caron Jacobson, Soyoung Kim, Zhongyu Feng, Babatunde Adedokun, Jiali Yan, Qian Huang, Kenny Hu, Timothy Best, Ioana Kloos, Grace Lee, Mehdi Hamadani, Marcelo Pasquini, Frederick Locke

Blood (2025) 146 (Supplement 1): 3606.

https://doi.org/10.1182/blood-2025-3606

Published: 2025

Journal Articles

Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease

Annelies J. Van Vuren, MD, Laurel Mendelsohn, BS, Richard van Wijk, PhD, Caterina P. Minniti, MD, John Baird, MD, Gregory J Kato, MD, Eduard J. van Beers, MD PhD

Blood (2019) 134 (Supplement_1): 2274.

https://doi.org/10.1182/blood-2019-124048

Published: 2019

Journal Articles

Inhibition of De Novo Pyrimidine Nucleotide Synthesis By the Novel DHODH Inhibitor PTC299 Induces Differentiation and/or Death of AML Cells

Marla Weetall, PhD, Kensuke Kojima, MD PhD, Sujan Piya, PhD, Christopher Trotta, PhD, John Baird, PhD, Kylie O'Keefe, Bansri Furia, Gautam M. Borthakur, MD, Robert Spiegel, MD

Blood (2019) 134 (Supplement_1): 5152.

https://doi.org/10.1182/blood-2019-124569

Published: 2019

Journal Articles

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel

Zinaida Good, PhD, Jay Y. Spiegel, MDFRCPC, Bita Sahaf, PhD, Meena B. Malipatlolla, Matthew J. Frank, MD PhD, John Baird, MD, Lori S Muffly, MD, Gursharan K. Claire, MPH, Juliana Craig, BA, Katherine A. Kong, Sean Bendall, PhD, David B Miklos, MD PhD, Crystal L. Mackall, MD

Blood (2019) 134 (Supplement_1): 779.

https://doi.org/10.1182/blood-2019-130815

Published: 2019

Journal Articles

PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells

Liangxian Cao, MD, Arthur Branstrom, PhD, John Baird, PhD, Christopher Trotta, PhD, Joseph Colacino, PhD, Marianne T. Santaguida, BSc, PhD, Diane Heiser, PhD BA, Mark Ma, PhD, Kensuke Kojima, MD PhD, Stuart Peltz, PhD, Edward O'Mara, MD, Robert Spiegel, MD, Marla Weetall, PhD

Blood (2017) 130 (Supplement 1): 1371.

https://doi.org/10.1182/blood.V130.Suppl_1.1371.1371

Published: 2017

Journal Articles

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Noelle V. Frey, MDMS, Selina Luger, MD, James Mangan, MD PhD, Alexis Zebrowski, BA, Alison W. Loren, MDMS, Hans Minderman, John Baird, MD, David L Porter, MD, Elizabeth O. Hexner, MD, Anita J. Kumar, MDMS, Marlise R. Luskin, MD, Alexander E Perl, MD, Martin Carroll, MD

Blood (2014) 124 (21): 3758.

https://doi.org/10.1182/blood.V124.21.3758.3758

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Trial-in-progress: A phase 2 randomized trial of remodeling intestinal microbiota using fecal microbiome transplant (FMT) among recipients of chimeric antigen receptor T cells (CAR T)

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

Real-world evaluation of health care resource utilization, clinical effectiveness, and safety of lisocabtagene maraleucel and axicabtagene ciloleucel administered in the outpatient (OP) setting for R/R large B-cell lymphoma (LBCL)

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)

Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease

Inhibition of De Novo Pyrimidine Nucleotide Synthesis By the Novel DHODH Inhibitor PTC299 Induces Differentiation and/or Death of AML Cells

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel

PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only